

31 Oct 2021 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: Lilly goes head-to-head in Alzheimer's; Roche eyes new opportunities for Lucentis; Novartis doubles down on innovation; BMS seeks growth amid generic threats; and the new head of Boehringer Ingelheim India talks to *Scrip*.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip*'s global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 29 October 2021, including: [Eli Lilly and Company](#) goes head-to-head in Alzheimer's; [Roche Holding AG](#) eyes new opportunities for Lucentis; [Novartis AG](#) doubles down on innovation; [Bristol Myers Squibb Company](#) seeks growth amid generic threats; and the new head of [Boehringer Ingelheim GmbH](#) in India talks to *Scrip*.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Lilly Targets Aduhelm With Aggressive Plans For Donanemab In Alzheimer's](#)" - Scrip, 26 Oct, 2021.)

(Also see "[Roche's Port Delivery System Approved, Paving The Way For Ophthalmology Expansion](#)" - Scrip, 22 Oct, 2021.)

(Also see "[Cosentyx And Entresto Keep Powering Novartis As Firm Mulls Sandoz Sale](#)" - Scrip, 26 Oct, 2021.)

(Also see "[BMS Focuses On Driving Future Growth As Revlimid Generic Launches Near](#)" - Scrip, 27

SCRIP

CITELINE COMMERCIAL

Oct, 2021.)

(Also see "[Podcast: B-Ingelheim India Chief On Strategy, Jardiance Challenge, Gender Balance In Pharma](#)" - Scrip, 27 Oct, 2021.)

[Click here to explore this interactive content online](#) 